**DUPONT E I DE NEMOURS & CO** Form 8-K April 24, 2001

\_\_\_\_\_\_

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 5(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) April 24, 2001

E. I. du Pont de Nemours and Company (Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction (Commission of Incorporation) File Number)

1-815

51-0014090 (I.R.S. Employer Identification No.)

1007 Market Street Wilmington, Delaware 19898 (Address of principal executive offices)

Registrant's telephone number, including area code: (302) 774-1000

\_\_\_\_\_\_

Item 5. Other Events

The Registrant files, pursuant to Regulation FD, its earnings news release dated April 24, 2001, entitled "DuPont Reports First Quarter 2001 Earnings," a copy of which is below. This earnings news release is also filed in connection with Debt and/or Equity Securities that may be offered on a delayed or continuous basis under Registration Statements on Form S-3 (No. 33-53327, No. 33-61339, No. 33-60069 and No. 333-86363).

April 24, 2001 WILMINGTON, Del. Contact: Clif Webb 302-774-4005

r-clifton.webb@usa.dupont.com

DUPONT REPORTS FIRST QUARTER 2001 EARNINGS

#### Summary

- o First quarter 2001 underlying earnings of \$.54 per share were in line with expectations, but 36 percent below first quarter 2000 earnings of \$.85 per share
- o Segment sales in first quarter 2001 of \$7.6 billion decreased 9 percent versus first quarter 2000. This reflects 7 percent lower volume and 2 percent lower U.S. dollar selling prices.
- o First quarter underlying after-tax operating income (ATOI) was \$734 million, 33 percent below first quarter 2000. ATOI margin was 10 percent.
- O Pharmaceuticals accounted for approximately one-third of the underlying ATOI decline. Excluding Pharmaceuticals, ATOI reductions also reflect a \$165 million impact from higher raw material costs and \$100 million from lower sales volume.
- O Worldwide local currency selling prices were up 1 percent. Adverse currency effects, principally from the weaker euro and Japanese yen, reduced first quarter worldwide segment sales by 3 percent.
- O Actions leading to business restructurings and personnel reductions to better align resources with the specific mission of each business are under way. One-time charges associated with these initiatives will be taken in the second quarter and have no impact on first quarter results.

# Earnings Comparisons (\$ per share diluted)

	1Q <b>'</b> 01	1Q'00
Underlying	.54	.85
One-Time Items	(.07)	(.09)
Reported	.47	.76

2

DuPont reported earnings before one-time items, of \$.54 per share for the first quarter, compared to \$.85 per share earned last year.

"We are taking the right steps to manage through a global economic slowdown," said Charles O. Holliday, Jr., DuPont chairman and chief executive officer. "As we take these steps, we are managing operating costs and capital spending in line with current economic conditions and streamlining businesses to sharpen competitiveness."

Global Sales and Income Highlights

For the quarter, consolidated sales totaled \$6.9 billion compared to \$7.6 billion in 2000. Segment sales, including transfers and a pro rata share of sales by equity affiliates, were \$7.6 billion, down 9 percent from \$8.3 billion in 2000. Net income was \$495 million versus \$803 million in 2000, resulting in earnings per share of \$.47 compared to \$.76 last year. The earnings decline

reflects significantly lower Pharmaceuticals results and reduced earnings across the company's chemicals and materials segments. The latter resulted principally from lower U.S. sales volumes, higher raw material costs, and a stronger U.S. dollar.

Net income before one-time items was \$567 million, compared to \$898 million in the first quarter of 2000, down \$331 million or 37 percent. One-time items are described in the notes to the accompanying financial statements and are summarized in the table below:

ONE-TIME ITEMS

	\$MM Pretax		\$MM After-	\$MM After-Tax		
	2001	2000	2001	2000		
Pioneer - In-Process R&D Revision		11		11		
Pioneer - Purchase Accounting	(133)	(347)	(83)	(215		
Asset Sale - Equity Securities		176		109		
Adoption of SFAS 133*	19		11			
1st Quarter - Total	(114)	(160)	(72)	(95		

\* Reflects the cumulative effect of a change in accounting principle. Effective January 1, 2001, the company adopted SFAS 133 - "Accounting for Derivative Instruments and Hedging Activities," as amended.

3

Regional segment sales and related variances for the first quarter 2001 compared with the first quarter 2000 are summarized below: FIRST QUARTER

FIRST QUARTER

	Segm	Segment Sales			% Change Due To		
	Q1'01 \$B	% Change vs. Q1'00	Local Price	Currency Effect	Volume	Pha	
Worldwide	7.6	(9)	1	(3)	(4)		
U.S.	3.7	(13)	1	0	(9)		
Europe	2.1	(3)	3	(7)	1		
Asia Pacific	1.1	(1)	1	(4)	2		

Canada, Mexico,
S. America 0.7 (9) 2 (2) (9)

- \* Includes impact from reduced ownership in DuPont Photomasks. In addition, the Pharmaceuticals segment has been isolated for purposes of this analysis.
- o Worldwide volumes declined 7 percent, including a 2 percent decline attributable to pharmaceuticals and 1 percent from portfolio changes.
- O U.S. first quarter sales volume (excluding Pharmaceuticals/Other) declined 9 percent versus 2000 principally reflecting lower volumes of fibers, automotive finishes, and white pigments.
- o European volume was up 1 percent and local currency prices up 3 percent. However, the stronger dollar reduced European sales by 7 percent.
- Asia Pacific sales decreased 1 percent, the first decline since the economic downturn in 1998. Marginally higher volume and local prices were more than offset by the negative impact of weaker currencies, particularly the Japanese yen.

Six Sigma

At the end of the current quarter, there were about 1,200 trained Black Belts and over 3,600 active projects. The potential pretax benefit from active projects was \$700 million, about the same as at year-end. The actual annualized pretax benefit of completed projects at the end of the current quarter was \$490 million, compared to \$370 million at year-end.

4

#### Business Segment Performance

Summarized below are comments on individual segment first quarter 2001 results excluding one-time items, compared to first quarter 2000 results:

- Performance Coatings & Polymers Sales were 12 percent lower than 2000 reflecting lower vehicle builds and lower refinish sales in the United States, as well as the weak euro. Increased raw material costs were a significant factor in lower results in Engineering Polymers and Elastomers, in addition to lower volumes. Segment ATOI declined 26 percent.
- Specialty Fibers Sales and ATOI were 5 percent and 22 percent lower, respectively. Continued earnings growth from Advanced Fibers Systems only partly offset lower Lycra(R) elastane earnings, which were adversely affected by lower U.S. dollar prices, higher raw material costs, and lower volume. Earnings for Nonwovens were essentially flat on modestly higher sales.
- Specialty Polymers ATOI increases in Fluoropolymers and the Electronic Technologies unit of DuPont iTechnologies only partly offset a decline in Packaging & Industrial Polymers earnings resulting from lower volumes and higher ethane costs. Results also declined in DuPont Surfaces and the Imaging Technologies unit of DuPont iTechnologies. Segment earnings decreased 21 percent on 5 percent lower sales.

- o Pigments & Chemicals ATOI declined 24 percent on 1 percent lower sales reflecting lower earnings in all strategic business units. Three percent lower worldwide volume was partly offset by 2 percent higher U.S. dollar prices. Segment earnings were negatively affected by high chlorine and energy costs in White Pigment & Mineral Products and by a litigation settlement in DuPont Chemical Solutions Enterprise.
- o Polyester Enterprise Sales were 4 percent lower, reflecting continuing depressed conditions in worldwide fibers markets. Margins continue to be reduced by lower prices and higher raw material and energy costs, resulting in a first quarter loss of \$8 million.
- o Nylon Enterprise Sales decreased 13 percent and ATOI declined 86 percent, principally reflecting the impact of a 40 percent increase in raw material costs (largely natural gas related), 15 percent lower volumes, and less favorable product mix. Sales declines were principally due to lower flooring and apparel volumes, particularly in the United States.
- o Agriculture & Nutrition Sales declined 3 percent and ATOI fell 23 percent reflecting lower earnings in both Crop Protection and Nutrition & Health. Crop Protection earnings were significantly affected by currency in Europe and Asia, and by a litigation settlement. Nutrition & Health results reflect high natural gas prices and weaker European volumes.

5

- o Pioneer Worldwide sales increased slightly, reflecting strong early season sales in the United States and southern Europe, partly offset by lower U.S. dollar prices due to the weak euro. Earnings increased 17 percent reflecting improved margins and a more favorable product mix.
- Pharmaceuticals The loss of \$64 million was primarily due to lower sales, as wholesaler inventories in the distribution channel continue to be reduced. Underlying demand for Sustiva(TM) efavirenz and Cardiolite(R) cardiac imaging agent grew 15 percent, and the Coumadin(R) (warfarin sodium tablets, USP) crystalline market position remains strong. The DuPont share of Cozaar(R)/Hyzaar(R) U.S. operating profits increased this quarter as of February 1. R&D and marketing expenses increased as planned. Major product sales are shown below:

(\$ in millions)	1Q 2001	1Q 2000
Coumadin(R)	26	100
Sustiva (TM)	55	96
Cardiolite(R)/Miraluma(TM)	18	40

#### Outlook

Based on demand signals observed in the first quarter in key markets, the company now anticipates that the global economic slowdown will similarly impact the manufacturing sector through the second quarter and perhaps into the second half of 2001. In the second quarter the company expects continued volume pressure due to macro economic factors; stabilizing energy and raw material costs, albeit at a higher level than second quarter last year; and normal seasonality for its portfolio of businesses.

- The company expects second quarter volumes to remain below 2000 levels in the United States in its chemical and materials businesses, although sequential declines should moderate considerably. In Europe and Asia, year-over-year volume growth is approaching zero, and continued strength of the U.S. dollar will likely result in negative revenue comparisons in the second quarter.
- O The agriculture related segments, as expected, are operating in a difficult U.S. farm economy and experiencing negative currency impacts during the first half selling season. In addition, poor weather conditions in North America, together with high fertilizer costs, are expected to result in lower corn acreage than last year. Accordingly, the company expects the full-year operating outlook for these segments will be moderately negative versus 2000.
- o Pharmaceuticals segment sales and earnings should improve in the second quarter, but ATOI losses are again expected. A return to more normal levels of sales and earnings is expected in the second half of the year.

6

The economic outlook for the second half of 2001 remains uncertain. However, key indicators suggest that declines in U.S. manufacturing and global automotive markets may be moderating. The company is encouraged by these trends, but continues to plan for a second half economy that is on balance, similarly challenging to the second half of last year.

"We will emerge from the current economic turbulence an even stronger company," Holliday said. "We have accelerated operational initiatives begun last year to manage costs and we are directing resources to businesses having the best long-term growth potential."

Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; and seasonality of agricultural products.

More information about segment results and highlights may be accessed on www.dupont.com via the "For Investors" web page.

# # #

4/24/01

7

### E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

CONSOLIDATED INCOME STATEMENT		ee Mon Mar	ch 3	31
(Dollars in millions, except per share)	:	2001 		2000
SALES Other Income(s)	\$	6 <b>,</b> 859	\$	7 <b>,</b> 59
Other Income(a)		170		
Total		7 <b>,</b> 029		7 <b>,</b> 94
Cost of Goods Sold and Other Expenses(b) Selling, General and Administrative Expenses Depreciation		4,486 757 327		4,85 75 35
Amortization of Goodwill and Other Intangible Assets Research and Development Expense Interest and Debt Expense		112 410 178		10 42 20
Purchase In-Process Research and Development(c)  Total		6,270		1) 6,68
INCOME BEFORE INCOME TAXES AND MINORITY INTERESTS Provision for Income Tax Expenses Minority Interests in Earnings of Consolidated Subsidiaries		759 272 3		1,25 43
INCOME BEFORE CUMULATIVE EFFECT OF A CHANGE IN ACCOUNTING PRINCIPLE		484		80
Cumulative Effect of a Change in Accounting Principle, Net of Income Taxes(d)		11		-
NET INCOME	\$ ==:	495	\$ ==	80
BASIC EARNINGS PER SHARE OF COMMON STOCK(e)  Income before Cumulative Effect of a Change in Accounting Principle Cumulative Effect of a Change in Accounting Principle		.46 .01	\$	. 7
Net Income	\$		\$ ==	.7
DILUTED EARNINGS PER SHARE OF COMMON STOCK(e)  Income before Cumulative Effect of a Change in Accounting Principle  Cumulative Effect of a Change in Accounting Principle	\$	.01	\$	. 7
Net Income	\$	.47	\$	. 7

\$ .35 \$ .3

8

#### FOOTNOTES TO CONSOLIDATED INCOME STATEMENT

- (a) First quarter 2000 includes a \$176 gain resulting from the sale by Pioneer of certain equity securities classified as available for sale.
- (b) In accordance with purchase accounting rules applied to the acquisition of the remaining 80 percent ownership interest in Pioneer on October 1, 1999, Pioneer inventory was increased to fair value. This inventory step-up generates noncash charges to cost of goods sold as the inventory on hand at the acquisition date is sold. Charges in first quarter 2001 and 2000 were \$133 and \$347, respectively.
- (c) Purchased in-process research and development represents the value assigned in a purchase business combination to research and development projects of the acquired business that were commenced but not yet completed at the date of acquisition, for which technological feasibility has not yet been established, and which have no alternative future use in research and development activities or otherwise. During first quarter 2000, a credit of \$11 was recorded based on revisions of preliminary purchase price allocations associated with the October 1, 1999 purchase of the remaining 80 percent ownership interest in Pioneer.
- (d) On January 1, 2001, the company adopted SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities," as amended.
- (e) Earnings per share are calculated on the basis of the following average number of common shares outstanding:

Three	Mont	hs	Ended
Ma	arch	31	

	Basic	Diluted
2001	1,042,168,259	1,047,973,561
2000	1,047,036,515	1,057,077,345

9

#### E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

CONSOLIDATED SEGMENT INFORMATION(a)	Three Months Ende		Ended	
(Dollars in millions)		2001 		2000
SEGMENT SALES(b) Agriculture & Nutrition	\$	609	\$	628

Nylon Enterprise Performance Coatings & Polymers Pharmaceuticals Pigments & Chemicals Pioneer Polyester Enterprise Specialty Fibers Specialty Polymers Other	960 1,458 205 951 929 545 858 1,039 81	1,109 1,653 389 960 921 567 905 1,091 123
Total Segment Sales Elimination of Intersegment Transfers Elimination of Equity Affiliate Sales Miscellaneous	 7,635 (146) (628) (2)	8,346 (159) (595)
CONSOLIDATED SALES	\$ 6,859	\$ 7,593
AFTER-TAX OPERATING INCOME (LOSS) Agriculture & Nutrition Nylon Enterprise Performance Coatings & Polymers Pharmaceuticals Pigments & Chemicals Pioneer(c) Polyester Enterprise Specialty Fibers Specialty Polymers Other	\$ 48 12 132 (64) 124 118 (8) 156 130 3	62 87 179 54 164 77 9 201 165
Total Segment ATOI Interest & Exchange Gains and Losses Corporate Expenses INCOME FROM OPERATIONS		\$ 998 (123) (72) 803

- (a) Certain reclassifications of segment data have been made to reflect changes in organizational structure.
- (b) Includes pro rata share of equity affiliate sales and intersegment transfers. Excludes sales of intermediates by DuPont to joint ventures within the Nylon Enterprise and Polyester Enterprise segments.
- (c) Includes noncash charges of \$83 and \$215 for first quarter 2001 and 2000, respectively, resulting from the sale of acquired Pioneer inventories which, in accordance with purchase accounting rules, were recorded at fair value on October 1, 1999. The first quarter 2000 charge was partly offset by a \$109 gain resulting from the sale of certain equity securities classified as available for sale and a credit of \$11 to reduce the preliminary purchase price allocated to acquired in-process research and development.

10

#### E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

SEGMENT SALES(a)
(1ST QUARTER 2001 VS. 1ST QUARTER 2000)

	Segm Three Mo: Mar	Percentage		
		Change	U.S. \$ Price	
Agriculture & Nutrition	\$ 609	(3)	(5)	
Nylon Enterprise	960	(13)	2	
Performance Coatings & Polymers	1,458	(12)	(3)	
Pharmaceuticals	205	(47)	0	
Pigments & Chemicals	951	(1)	2	
Pioneer	929	1	(2)	
Polyester Enterprise	545	(4)	(4)	
Specialty Fibers	858	(5)	(6)	
Specialty Polymers	1,039	(5)	2	
Other	81	(34)	0	
Total	<b>\$7,635</b>	(9)	(2)	
	========			

<sup>(</sup>a) Includes intersegment transfers and pro rata share of equity affiliate

SEGMENT INFORMATION EXCLUDING IMPACT OF ONE-TIME ITEMS -	Three Months Ended March 31		
(Dollars in millions)	2001	2000	
AFTER-TAX OPERATING INCOME (LOSS) Agriculture & Nutrition	\$ 48	\$ 62	
Nylon Enterprise	12	87	
Performance Coatings & Polymers	132	179	
Pharmaceuticals	(64)	54	
Pigments & Chemicals	124	164	
Pioneer	201	172	
Polyester Enterprise	(8)	9	
Specialty Fibers	156	201	
Specialty Polymers	130	165	
Other	3	_	
Total Segment ATOI	734	1,093	
Interest & Exchange Gains (Loss)	(97)	(123)	
Corporate Expenses	(70)	(72)	
INCOME FROM OPERATIONS	\$ 567	\$ 898	

<sup>(</sup>b) Reflects reduced interest in DuPont Photomasks, Inc.

11

#### E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

FINANCIAL SUMMARY

(Dollars in millions, except per share)

	2001	Three Months Ende March 31 2000
Selected Income Statement Data -		
Excluding Impact of One-Time Items and		
Cumulative Effect of a Change in Accounting Principle		
Consolidated Sales	\$6,859	\$7 <b>,</b> 593
Segment Sales	7,635	8,346
Segment ATOI	734	1,093
EBIT	1,086	1,636
EBITDA	1,525	2,094
Income from Operations	567	898
EPS - Diluted	0.54	0.85

	1st Quarter 2001 Vs. 1st Quarter 2000
Segment ATOI Variance Analysis - Excluding Impact of One-Time Items Local Prices Volume Costs Other Currency	\$ 75 (230) (167) 13 (50)
Total	\$ (359)

12

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

E. I. DU PONT DE NEMOURS AND COMPANY (Registrant)

/s/ D. B. Smith

D. B. Smith

Assistant Controller

April 24, 2001